| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BIRB 0796 | FIMM | pan-cancer | AAC | 0.02 | 0.9 |